Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Tomohide, Sugiyama"'
Autor:
Yutaka Yamada, Hisao Imai, Tomohide Sugiyama, Hiroyuki Minemura, Kenya Kanazawa, Takashi Kasai, Koichi Minato, Kyoichi Kaira, Takayuki Kaburagi
Publikováno v:
Medicina, Vol 57, Iss 9, p 929 (2021)
Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non-small-cell lung cancer (NSCLC) harboring drug-sensitive EGFR mutation
Externí odkaz:
https://doaj.org/article/5e80cb40334f4c798d6ed351f108b7e3
Autor:
Takashi Kasai, Kiyoshi Mori, Tomohide Sugiyama, Nobuyuki Koyama, Yoichi Nakamura, Fumiyoshi Ohyanagi, Hiroki Fukuda, Eishin Hoshi, Kunihiko Kobayashi, Mitsuo Nakayama
Publikováno v:
International Journal of Clinical Oncology. 27:1841-1848
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58e4f4bf31b74fe490174cf94cb28de7
https://doi.org/10.1007/s10147-022-02241-6
https://doi.org/10.1007/s10147-022-02241-6
Autor:
Mie Kotake, Hisao Imai, Kyoichi Kaira, Hideki Endoh, Yutaka Yamada, Takayuki Kaburagi, Moriyuki Kiyoshima, Tomohide Sugiyama, Yoichi Nakamura, Takashi Kasai, Haruhisa Matsuguma, Hiroyuki Minemura, Kenya Kanazawa, Hiroyuki Suzuki, Atsushi Fujita, Koichi Minato
Publikováno v:
Chemotherapy. 67:142-151
Introduction: Data on the clinical outcomes of patients receiving adjuvant chemotherapy for surgically resected high-grade pulmonary neuroendocrine carcinoma (HGNEC) (large-cell neuroendocrine carcinoma and small-cell lung cancer) are limited. This s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d1ed9d9d46efaa9f942b5b83555cac
https://doi.org/10.1159/000524077
https://doi.org/10.1159/000524077
Autor:
Koichi Minato, Hiroyuki Suzuki, Tomohide Sugiyama, Hisao Imai, Hiroyuki Minemura, Takashi Kasai, Yutaka Yamada, Takayuki Kaburagi, Yuki Ozaki, Kenya Kanazawa, Hiroshi Yokouchi, Mitsunori Higuchi, Hiroshi Moriya, Yoko Shibata, Kyoichi Kaira
Publikováno v:
Thoracic Cancer
Background Nivolumab is known to demonstrate superior overall survival compared with docetaxel in pretreated non‐small cell lung cancer (NSCLC) patients. Programmed death‐ligand 1 (PD‐L1) expression is reported to predict the outcome of treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a833e0cd73326f01b8f56235d4780fe
https://doi.org/10.1111/1759-7714.13695
https://doi.org/10.1111/1759-7714.13695
Autor:
Takashi Osaki, Kyoichi Kaira, Hisao Imai, Kenya Kanazawa, Keita Mori, Satoshi Wasamoto, Yukihiro Umeda, Ou Yamaguchi, Koichi Minato, Shinichi Ishihara, Norimitsu Kasahara, Kensuke Suzuki, Tomohide Sugiyama, Hisashi Ishii, Hiroshi Kagamu, Hiroyuki Minemura, Mie Kotake, Ichiro Naruse, Junji Uchino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:761-771
Immune checkpoint inhibitors (ICIs) are an effective subsequent-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However, it remains unclear whether the efficacy and safety of subsequent-line ICI monotherapy in elderly pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcfec0272bc7ac01b698af3d00d28742
https://doi.org/10.1007/s00280-020-04055-7
https://doi.org/10.1007/s00280-020-04055-7
Autor:
Tomoyasu Mimori, Takehito Shukuya, Ryo Ko, Yusuke Okuma, Tomonobu Koizumi, Hisao Imai, Yuichi Takiguchi, Eisaku Miyauchi, Hiroshi Kagamu, Tomohide Sugiyama, Keisuke Azuma, Yukiko Namba, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Kunihiko Kobayashi, Kazuhisa Takahashi
Publikováno v:
Cancers; Volume 14; Issue 2; Pages: 331
Cancers, Vol 14, Iss 331, p 331 (2022)
Cancers
Cancers, Vol 14, Iss 331, p 331 (2022)
Cancers
Simple Summary Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::643f811c014097c66dbbb4d5067c2eb7
Autor:
Hiroyuki Minemura, Koichi Minato, Kenya Kanazawa, Kyoichi Kaira, Hisao Imai, Tomohide Sugiyama, Takayuki Kaburagi, Takashi Kasai, Yutaka Yamada
Publikováno v:
Medicina
Volume 57
Issue 9
Medicina, Vol 57, Iss 929, p 929 (2021)
Volume 57
Issue 9
Medicina, Vol 57, Iss 929, p 929 (2021)
Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non-small-cell lung cancer (NSCLC) harboring drug-sensitive EGFR mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eac694a8e0d42ec50ce1a87a2292497
Autor:
Nobutoshi Morozumi, Takashi Osaki, Tomohide Sugiyama, Yukihiro Umeda, Koichi Minato, Hisao Imai, Mie Kotake, Hisashi Ishii, Hirokazu Taniguchi, Satoshi Wasamoto, Hiroshi Kagamu, Ou Yamaguchi, Kyoichi Kaira, Keita Mori, Kensuke Suzuki, Junji Uchino, Takashi Kasai, Hiroyuki Minemura
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:457-466
Pembrolizumab is an effective front-line treatment for advanced non-small cell lung cancer (NSCLC) in patients expressing high levels of programmed death-ligand 1 (PD-L1). However, it is unclear whether first-line pembrolizumab has similar efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69c45e8a73431ed8ca93d08492748973
https://doi.org/10.1007/s00432-019-03072-1
https://doi.org/10.1007/s00432-019-03072-1
Autor:
Akihiro Bessho, Tomoya Fukui, Nobuhiko Seki, Jiichiro Sasaki, Akinobu Hamada, Satoshi Igawa, Katsuhiko Naoki, Noriyuki Masuda, Yoshiro Nakahara, Hiroaki Okamoto, Shinobu Hosokawa, Nobuaki Fukamatsu, Yukiko Nakamura, Takaaki Tokito, Takashi Kasai, Tomohide Sugiyama, Sakiko Otani
Publikováno v:
Investigational new drugs. 39(2)
Background Amrubicin (AMR) is a completely synthetic 9-aminoanthracycline and clinically active against non-small cell lung cancer (NSCLC). We conducted a phase I study of AMR and erlotinib (ERL) combination therapy in previously treated patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8534c99c0ac043914941e0d0397e8f5
https://pubmed.ncbi.nlm.nih.gov/33159674
https://pubmed.ncbi.nlm.nih.gov/33159674
Autor:
Mie Kotake, Takayuki Kaburagi, Tomohide Sugiyama, Yoichi Nakamura, Yoko Shibata, Takashi Kasai, Koichi Minato, Hisao Imai, Kyoichi Kaira, Hiroyuki Minemura, Yutaka Yamada, Kenya Kanazawa
Publikováno v:
Thoracic Cancer. 9:1699-1706
Background Topotecan is one of the most active chemotherapeutic drugs for small cell lung cancer (SCLC). However, its efficacy in elderly patients with SCLC has not been validated. This study evaluated the feasibility and efficacy of topotecan monoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b76f47fc48560857be814fbe8d0e01e
https://doi.org/10.1111/1759-7714.12884
https://doi.org/10.1111/1759-7714.12884